Stoke Therapeutics, Inc. $STOK Shares Sold by Troluce Capital Advisors LLC

Key Points

• Troluce Capital Advisors cut its Stoke Therapeutics stake by 24% in the second quarter, selling 156,384 shares and retaining 496,416 shares valued at approximately $16.2 million.
• Other institutional activity was mixed: Wellington Management increased its position by 13.7%, while several investors, including Seven Fleet Capital and Palo Alto Investors, initiated new stakes.
• Stoke reported a quarterly loss of $0.93 per share, missing estimates, while insiders sold 34,373 shares worth about $1.07 million over the past three months. Despite the selling, analysts maintain a “Moderate Buy” consensus with an average price target of $44.25 versus the stock’s $29.81 opening price.

Troluce Capital Advisors LLC decreased its stake in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 24.0% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 496,416 shares of the company's stock after selling 156,384 shares during the quarter. Stoke Therapeutics makes up 1.7% of Troluce Capital Advisors LLC's holdings, making the stock its 6th largest position. Troluce Capital Advisors LLC owned about 0.77% of Stoke Therapeutics worth $16,243,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Seven Fleet Capital Management LP purchased a new position in Stoke Therapeutics during the second quarter valued at approximately $255,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in Stoke Therapeutics by 12.1% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 65,228 shares of the company's stock worth $2,134,000 after purchasing an additional 7,043 shares in the last quarter. Wellington Management Group LLP boosted its position in Stoke Therapeutics by 13.7% in the 2nd quarter. Wellington Management Group LLP now owns 3,519,301 shares of the company's stock worth $115,152,000 after purchasing an additional 423,601 shares in the last quarter. Palo Alto Investors LP purchased a new stake in Stoke Therapeutics in the 2nd quarter worth approximately $2,769,126. Finally, Capstone Investment Advisors LLC acquired a new stake in shares of Stoke Therapeutics during the 2nd quarter worth approximately $314,000.

Insider Buying and Selling

In other Stoke Therapeutics news, General Counsel Jonathan Allan sold 2,861 shares of the business's stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $32.03, for a total transaction of $91,637.83. Following the completion of the sale, the general counsel directly owned 21,225 shares in the company, valued at approximately $679,836.75. The trade was a 11.88% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Barry Ticho sold 5,545 shares of the stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $30.67, for a total value of $170,065.15. Following the transaction, the insider directly owned 20,110 shares of the company's stock, valued at $616,773.70. The trade was a 21.61% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 34,373 shares of company stock worth $1,068,939. Insiders own 9.60% of the company's stock.

Stoke Therapeutics Stock Performance

NASDAQ:STOK opened at $29.81 on Friday. The company has a fifty day moving average of $31.17 and a two-hundred day moving average of $32.20. The stock has a market capitalization of $1.92 billion, a PE ratio of -8.93 and a beta of 1.23. Stoke Therapeutics, Inc. has a fifty-two week low of $19.55 and a fifty-two week high of $40.22.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last announced its earnings results on Monday, August 3rd. The company reported ($0.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.80) by ($0.13). Stoke Therapeutics had a negative net margin of 753.60% and a negative return on equity of 59.36%. The company had revenue of $9.32 million during the quarter, compared to analyst estimates of $4.89 million. Research analysts forecast that Stoke Therapeutics, Inc. will post -3.52 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts recently issued reports on STOK shares. The Goldman Sachs Group started coverage on shares of Stoke Therapeutics in a research note on Monday, July 13th. They issued a "buy" rating and a $44.00 target price for the company. Weiss Ratings restated a "sell (d)" rating on shares of Stoke Therapeutics in a research report on Friday, August 7th. Canaccord Genuity Group cut their price objective on shares of Stoke Therapeutics from $60.00 to $58.00 and set a "buy" rating for the company in a report on Tuesday, August 4th. BTIG Research reiterated a "buy" rating and issued a $39.00 price objective on shares of Stoke Therapeutics in a research report on Monday, May 11th. Finally, Chardan Capital reissued a "buy" rating and set a $35.00 target price on shares of Stoke Therapeutics in a research note on Tuesday, August 4th. Ten investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $44.25.

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company's lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source